Algernon Announces Positive Feedback From Health Canada For Ifenprodil Covid-19 Phase 2 Human Trial

 Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has received positive feedback from Health Canada on the Company’s plan to conduct a phase 2 COVID-19 clinical study in Canada, with its repurposed drug NP-120 (Ifenprodil).

The Company believes that Ifenprodil is a drug that could reduce both the severity and duration of a COVID-19 infection.

Based on the feedback, which came from Health Canada’s Office of Clinical Trials (OCT), the Company has already begun preparing a formal Clinical Trial Application (CTA) to begin a phase 2 clinical trial with a focus on more severely affected patients with COVID-19. On approval, the Company will begin working to initiate the trial as soon as possible.

The Company plans to submit the CTA to Health Canada for approval of the phase 2 clinical trial within the next week and has been advised that approvals for COVID-19 related applications are being expedited.

In addition to advancing Ifenprodil towards a human trial approval in Canada, the Company is also working to support a planned investigator-led Ifenprodil COVID-19 clinical trial in South Korea, a sponsored trial in Australia and has also filed a pre-IND application for a phase 2 COVID-19 clinical trial with the U.S. FDA.

“This was very good news for the Company,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “Receiving positive feedback from a major regulatory body is another significant step as we work to investigate our repurposed drug Ifenprodil as a possible therapeutic treatment for COVID-19.”-Finance Yahoo